Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
02-08-2017, 09:46 AM
GW Pharmas cannabis-derived combo med helps brain cancer patients
by <a data-ipb="nomediaparse" href="http://www.fiercebiotech.com/author/ben-adams">Ben Adams</a> | Feb 7, 2017
After failing in an ulcerative colitis test a few yearsback, GW Pharmas cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor.
In the phase 2 study,the U.K. biopharmas cannabidiol (CBD) and tetrahydrocannabinol (THC) candidate, both of which are active ingredients derived from cannabis, showed positive top-line results from an exploratory placebo-controlled trial in 21 patients with recurrent glioblastoma multiforme, or GBM, a particularly aggressive brain tumor that has a poor prognosis.
The London-based companys trial showed that those with recurrent GBM treated with THC:CBD had an 83% one-year survival rate, compared with 53% for patients in the placebo cohort (although the p-value was close at 0.042).
After an initial safety test, the trial went into a controlled phase where 12 patients were randomized to THC:CBD as add-on therapy, compared with nine patients randomized to placebo (plus standard of care).....
<a data-ipb="nomediaparse" href="http://www.fiercebiotech.com/biotech/gw-pharma-s-cannabis-derived-combo-med-helps-brain-cancer-patients">http://www.fiercebiotech.com/biotech/gw-pharma-s-cannabis-derived-combo-med-helps-brain-cancer-patients</a>
by <a data-ipb="nomediaparse" href="http://www.fiercebiotech.com/author/ben-adams">Ben Adams</a> | Feb 7, 2017
After failing in an ulcerative colitis test a few yearsback, GW Pharmas cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor.
In the phase 2 study,the U.K. biopharmas cannabidiol (CBD) and tetrahydrocannabinol (THC) candidate, both of which are active ingredients derived from cannabis, showed positive top-line results from an exploratory placebo-controlled trial in 21 patients with recurrent glioblastoma multiforme, or GBM, a particularly aggressive brain tumor that has a poor prognosis.
The London-based companys trial showed that those with recurrent GBM treated with THC:CBD had an 83% one-year survival rate, compared with 53% for patients in the placebo cohort (although the p-value was close at 0.042).
After an initial safety test, the trial went into a controlled phase where 12 patients were randomized to THC:CBD as add-on therapy, compared with nine patients randomized to placebo (plus standard of care).....
<a data-ipb="nomediaparse" href="http://www.fiercebiotech.com/biotech/gw-pharma-s-cannabis-derived-combo-med-helps-brain-cancer-patients">http://www.fiercebiotech.com/biotech/gw-pharma-s-cannabis-derived-combo-med-helps-brain-cancer-patients</a>